AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20922772 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 167
Study 19016711 — intervention group
Group type: EXPERIMENTAL
Intervention: Talarozole (0.35% or 0.07%)
Number of subjects: 16
Study 19016711 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 16
Study 17723127 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin 2850 antifactor Xa units once daily for 3 weeks
Number of subjects: 113
Study 17723127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 17723127 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin and Placebo
Number of subjects: 113
Study 14739870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation
Number of subjects: 336
Study 14739870 — intervention group
Group type: COMPARATOR
Intervention: Mobilization
Number of subjects: 336
Study 14739870 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse reactions (general)
Number of subjects: 336
Study 11719833 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose Bay 27‐9955 200 mg
Number of subjects: 14
Study 11719833 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose Bay 27‐9955 70 mg
Number of subjects: 14
Study 11719833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9604731 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam-FDDF (40 mg)
Number of subjects: 40
Study 9604731 — intervention group
Group type: COMPARATOR
Intervention: Naproxen sodium (550 mg)
Number of subjects: 40
Study 7798839 — intervention group
Group type: EXPERIMENTAL
Intervention: Total polycythemic infants
Number of subjects: 68
Study 7798839 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic polycythemic infants
Number of subjects: 68
Study 7798839 — intervention group
Group type: COMPARATOR
Intervention: Control group (twin sibs)
Number of subjects: 68
Study 7798839 — intervention group
Group type: COMPARATOR
Intervention: Control group (excluding twin sibs)
Number of subjects: 68
Study 7798839 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial plasma exchange transfusion in asymptomatic infants
Number of subjects: 68
Study 7798839 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birthweight and small for gestational age infants
Number of subjects: 68
Study 2899196 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach villages (intervention)
Number of subjects: 0
Study 2899196 — intervention group
Group type: COMPARATOR
Intervention: Control villages (control)
Number of subjects: 0
Study 2899196 — intervention group
Group type: EXPERIMENTAL
Intervention: NCDDP promotion of better treatment
Number of subjects: 0
Study 31221553 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS to the left DLPFC
Number of subjects: 20
Study 31221553 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study 27179290 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal attainment method
Number of subjects: 212
Study 27179290 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal attainment
Number of subjects: 212
Study 25884717 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended Learning (BL) approach
Number of subjects: 147
Study 25884717 — intervention group
Group type: COMPARATOR
Intervention: Didactic Learning (DL) approach
Number of subjects: 147
Study 23766642 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pelvic floor muscle exercise (PFE) every day
Number of subjects: 66
Study 23766642 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PFE)
Number of subjects: 66
Study 21239976 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA (Thoracic Epidural Anesthesia)
Number of subjects: 654
Study 21239976 — intervention group
Group type: COMPARATOR
Intervention: GA (General Anesthesia)
Number of subjects: 654
Study 20166432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefteram pivoxil (test preparation)
Number of subjects: 24
Study 20166432 — intervention group
Group type: COMPARATOR
Intervention: Cefteram pivoxil (reference preparation)
Number of subjects: 24
Study 16770243 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (BAS)
Number of subjects: 99
Study 16770243 — intervention group
Group type: COMPARATOR
Intervention: Muromonab (OKT3)
Number of subjects: 99
Study 16770243 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (BAS) and Muromonab (OKT3)
Number of subjects: 99
Study 15585778 — intervention group
Group type: EXPERIMENTAL
Intervention: cis‐9,trans‐11 CLA (0.59, 1.19, and 2.38 g/d)
Number of subjects: 0
Study 15585778 — intervention group
Group type: EXPERIMENTAL
Intervention: trans‐10,cis‐12 CLA (0.63, 1.26, and 2.52 g/d)
Number of subjects: 0
Study 15585778 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 11745270 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A: Twice-daily TBI (1.7 Gy for 3 days, total 10.2 Gy)
Number of subjects: 82
Study 11745270 — intervention group
Group type: COMPARATOR
Intervention: Protocol B: Once-daily TBI (3 Gy for 4 days, total 12 Gy)
Number of subjects: 82
Study 11745270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 82
Study 9011596 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (5 x 500 U intravenously over a 14-day period before surgery)
Number of subjects: 76
Study 9011596 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 76
Study 8238222 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (50 mg/ml for five minutes)
Number of subjects: 55
Study 8238222 — intervention group
Group type: COMPARATOR
Intervention: Control (no intraoperative 5-fluorouracil)
Number of subjects: 55
Study 3608729 — intervention group
Group type: EXPERIMENTAL
Intervention: Total serum bile acids (TSBA)
Number of subjects: 429
Study 3608729 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated cholic acid (CCA)
Number of subjects: 429
Study 3608729 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartate aminotransferase
Number of subjects: 429
Study 3608729 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential aspartate aminotransferase measurement followed by CCA
Number of subjects: 429
Study 31295625 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional vocal sound (happy/angry)
Number of subjects: 0
Study 31295625 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional sounds (happy/angry)
Number of subjects: 0
Study 31295625 — intervention group
Group type: COMPARATOR
Intervention: Congruent emotional cues
Number of subjects: 0
Study 31295625 — intervention group
Group type: COMPARATOR
Intervention: Control study
Number of subjects: 0
Study 28222649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid
Number of subjects: 50
Study 28222649 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical washing with tranexamic acid
Number of subjects: 50
Study 28222649 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde tranexamic acid through drain
Number of subjects: 50
Study 28222649 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tranexamic acid)
Number of subjects: 50
Study 24564346 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten and milk diet
Number of subjects: 0
Study 24564346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23842829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 33
Study 23842829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 21816223 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprouts (40 g)
Number of subjects: 16
Study 21816223 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli supplement (6 pills)
Number of subjects: 16
Study 21816223 — intervention group
Group type: COMPARATOR
Intervention: Alfalfa sprouts (negative control)
Number of subjects: 16
Study 21816223 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills (negative control)
Number of subjects: 16
Study 19378637 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of the Tuskegee Syphilis Study (TSS)
Number of subjects: 1162
Study 19378637 — intervention group
Group type: COMPARATOR
Intervention: Previous findings from the 1999-2000 4-City TLP Study
Number of subjects: 1162
Study 17684633 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 118
Study 17684633 — intervention group
Group type: COMPARATOR
Intervention: Tetanus control vaccine
Number of subjects: 118
Study 16087026 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 100
Study 16087026 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 100
Study 12074614 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase injection and aspiration
Number of subjects: 50
Study 12074614 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision
Number of subjects: 50
Study 9501748 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI), paroxetine, 20 mg/day
Number of subjects: 51
Study 9501748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 7706154 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine alarm
Number of subjects: 1
Study 2244675 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation through the nose from a pressurized aerosol attached to a spacer device
Number of subjects: 30
Study 2244675 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 30
Study 666948 — intervention group
Group type: EXPERIMENTAL
Intervention: L(‐)‐bupivacaine at 7.69 mmol/l
Number of subjects: 17
Study 666948 — intervention group
Group type: EXPERIMENTAL
Intervention: D(+)‐bupivacaine at 7.69 mmol/l
Number of subjects: 17
Study 666948 — intervention group
Group type: EXPERIMENTAL
Intervention: L(‐)‐bupivacaine at 0.48 mmol/l
Number of subjects: 17
Study 666948 — intervention group
Group type: EXPERIMENTAL
Intervention: L(‐)‐bupivacaine from 0.48‐3.84 mmol/l
Number of subjects: 17
Study 666948 — intervention group
Group type: EXPERIMENTAL
Intervention: D(+)‐bupivacaine from 0.48‐3.84 mmol/l
Number of subjects: 17
Study 666948 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 17
Study 31023759 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (80 mg/kg/day, maximum 980 mg of amoxicillin in two-divided doses) for 8 days
Number of subjects: 314
Study 31023759 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal volume and dosing frequency) for 8 days
Number of subjects: 314
Study 31023759 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 314
Study 31023759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 28953325 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line protease inhibitor (PI)-based ART
Number of subjects: 928
Study 25501623 — intervention group
Group type: EXPERIMENTAL
Intervention: MCPB system
Number of subjects: 78
Study 25501623 — intervention group
Group type: COMPARATOR
Intervention: CCPB system
Number of subjects: 78
Study 24324331 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle and functional exercise program (LiFE)
Number of subjects: 0
Study 24324331 — intervention group
Group type: COMPARATOR
Intervention: Structured exercise program (control)
Number of subjects: 0
Study 21508140 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 150 mg sc once daily for 4 weeks
Number of subjects: 19
Study 21508140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 21508140 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 19
Study 19080072 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg (Group 1, n=153)
Number of subjects: 456
Study 19080072 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril maleate and folic acid tablet at the ratio of 10/0.4 (Group 2, n=151)
Number of subjects: 456
Study 19080072 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril maleate and folic acid tablet at the ratio of 10/0.8 (Group 3, n=152)
Number of subjects: 456
Study 16571963 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop propofol target control infusion
Number of subjects: 164
Study 16571963 — intervention group
Group type: COMPARATOR
Intervention: Manual propofol target control infusion
Number of subjects: 164
Study 12722174 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 45 mg per day for 2 weeks
Number of subjects: 17
Study 12722174 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 17
Study 12722174 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 45 mg per day
Number of subjects: 17
Study 12722174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 12722174 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 17
Study 10932665 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet (Lofquist cuff, inflated to 120 mmHg)
Number of subjects: 50
Study 10932665 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet
Number of subjects: 50
Study 9298123 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin-positive dendritic cells in psoriatic lesions
Number of subjects: 0
Study 9298123 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin and HLA-DR immunoreactivity
Number of subjects: 0
Study 9298123 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin-positive cells
Number of subjects: 0
Study 7939938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansimef 1 tab/week (group 1)
Number of subjects: 1407
Study 7939938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansimef 1 tab/2 weeks (group 2)
Number of subjects: 1407
Study 7939938 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine 300 mg base weekly plus Fansidar 1 tab/week (group 3)
Number of subjects: 1407
Study 7939938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansimef 1/2 tab/week (group 4)
Number of subjects: 1407
Study 7939938 — intervention group
Group type: EXPERIMENTAL
Intervention: Lariam 1/2 tab/week (group 5)
Number of subjects: 1407
Study 7939938 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine plus Fansidar (group 6)
Number of subjects: 1407
Study 3521245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (700,000 units)
Number of subjects: 52
Study 3521245 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline solution)
Number of subjects: 52
Study 3521245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 52
Study 3521245 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study 29658441 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) combined with Cognitive Training (Cog) for 10 sessions (D0-D11)
Number of subjects: 24
Study 29658441 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Training (Cog) only (sham tDCS)
Number of subjects: 24
Study 29658441 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) combined with Cognitive Training (Cog)
Number of subjects: 24
Study 27525994 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble suppression of tumorigenicity-2 (day 0)
Number of subjects: 826
Study 27525994 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (day 0)
Number of subjects: 826
Study 27525994 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble suppression of tumorigenicity-2 (day 3)
Number of subjects: 826
Study 27525994 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (day 3)
Number of subjects: 826
Study 27525994 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble suppression of tumorigenicity-2 (day 3 weaning assessment)
Number of subjects: 826
Study 27525994 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (day 3 weaning assessment)
Number of subjects: 826
Study 27525994 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble suppression of tumorigenicity-2 (spontaneous breathing trial)
Number of subjects: 826
Study 27525994 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (spontaneous breathing trial)
Number of subjects: 826
Study 27525994 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble suppression of tumorigenicity-2 (need for reintubation)
Number of subjects: 826
Study 27525994 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (need for reintubation)
Number of subjects: 826
Study 24796043 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging acupoint embedment therapy, applied twice during the menstrual cycle (3 days before menstruation and during the 12th-14th days of menstruation) using specific acupoints.
Number of subjects: 70
Study 24796043 — intervention group
Group type: COMPARATOR
Intervention: Fenbid, 0.3 g orally, twice a day, starting 3 days before menstruation until pain relief, for 3 menstrual cycles.
Number of subjects: 70
Study 24796043 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging acupoint embedment therapy
Number of subjects: 70
Study 24490264 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-dose multivitamins and multiminerals
Number of subjects: 1708
Study 24490264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1708
Study 21649815 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bleaching agents (glycolic acid, kojic acid, lipohydroxyacid, and Vitreoscilla extract) applied daily for 3 months
Number of subjects: 24
Study 18294022 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial magnetic stimulation (TMS) administered 5 times per week at 10 pulses per second, at 120% of motor threshold, for a total of 3000 pulses/session.
Number of subjects: 158
Study 17197740 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (platinum-based)
Number of subjects: 0
Study 17197740 — intervention group
Group type: EXPERIMENTAL
Intervention: Uracil-tegafur
Number of subjects: 0
Study 14642411 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil
Number of subjects: 6
Study 14642411 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi‐liquid margarine
Number of subjects: 6
Study 14642411 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft margarine
Number of subjects: 6
Study 14642411 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortening
Number of subjects: 6
Study 14642411 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional stick margarine
Number of subjects: 6
Study 14642411 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter
Number of subjects: 6
Study 11009229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 24
Study 11009229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1.0 mg/kg
Number of subjects: 24
Study 11009229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9372379 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral diet (free amino acid and small peptide)
Number of subjects: 30
Study 9372379 — intervention group
Group type: COMPARATOR
Intervention: Parenteral support (isonitrogenous isocaloric)
Number of subjects: 30
Study 1589282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological therapy for acute spinal cord injury
Number of subjects: 0
Study 3331863 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tramadol
Number of subjects: 40
Study 3331863 — intervention group
Group type: COMPARATOR
Intervention: 100 mg pethidine
Number of subjects: 40
Study 29861256 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar taping in addition to routine physiotherapy
Number of subjects: 30
Study 29861256 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy (Control)
Number of subjects: 30
Study 29861256 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar taping
Number of subjects: 30
Study 27303100 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 160 mg daily
Number of subjects: 76
Study 27303100 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 40 mg daily
Number of subjects: 76
Study 24115765 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 31
Study 24115765 — intervention group
Group type: COMPARATOR
Intervention: Bariatric surgery
Number of subjects: 31
Study 22892753 — intervention group
Group type: EXPERIMENTAL
Intervention: All‐Bond SE (Bisco Inc)
Number of subjects: 200
Study 22892753 — intervention group
Group type: EXPERIMENTAL
Intervention: All‐Bond 3 (Bisco Inc)
Number of subjects: 200
Study 22892753 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step Plus (Bisco Inc)
Number of subjects: 200
Study 22892753 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study 20819621 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid hemodilution (HCT < 35%, n = 56)
Number of subjects: 115
Study 20819621 — intervention group
Group type: COMPARATOR
Intervention: Slow hemodilution (HCT >= 35%, n = 59)
Number of subjects: 115
Study 20819621 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid hemodilution (HCT < 35%)
Number of subjects: 115
Study 20819621 — intervention group
Group type: COMPARATOR
Intervention: Slow hemodilution (HCT >= 35%)
Number of subjects: 115
Study 19082796 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoshui decoction (XSD) combined with intrapleural perfusion of cisplatin
Number of subjects: 51
Study 19082796 — intervention group
Group type: COMPARATOR
Intervention: Intrapleural perfusion of cisplatin (control)
Number of subjects: 51
Study 17328449 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical management
Number of subjects: 0
Study 17328449 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 14574046 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning objectives checklist card
Number of subjects: 0
Study 14574046 — intervention group
Group type: COMPARATOR
Intervention: Control group (no checklist card)
Number of subjects: 0
Study 10341115 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine administered orally every 2 hr, six times per day for 10 days
Number of subjects: 0
Study 10341115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0